Original ArticleTATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
Under an Elsevier user license
open archive
Key words
combination
EGFR mutation
non-small cell lung cancer
osimertinib
phase I
Cited by (0)
Note: This study was previously presented at the following. Poster presented by Geoffrey Oxnard at the ASCO 2015 American Society of Clinical Oncology Annual Meeting, May 29–June 2, 2015, Chicago, USA; J Clin Oncol. 2015;33(15):S2509-2509. Presented by Myung-Ju Ahn at the 6th IASLC/ESMO European Lung Cancer Conference, April 13–16, 2016, Geneva, Switzerland; Abstract 136O; J Thorac Oncol. 2016;11(4):S115. Presented by Suresh Ramalingam at the American Association for Cancer Research Annual Meeting 2019, March 29–April 3, 2019, Atlanta, USA; Abstract CT034.
© 2020 European Society for Medical Oncology. Published by Elsevier Ltd.